Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer

Roberto Díaz; Jorge Aparicio; Jorge Molina; Laura Palomar; Alejandra Giménez; José Ponce; Ángel Segura; José Gómez-Codina

首页> 外文期刊>Medical Oncology >Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer

【24h】

Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer

机译：伊立替康和/或奥沙利铂联合化疗治疗转移性结直肠癌患者严重毒性的临床预测指标

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Little has been published regarding clinical predictors of severe toxicity in patients with metastatic colorectal cancer (CRC) treated with combination chemotherapy (CT) with oxaliplatin and/or irinotecan.

机译：关于用奥沙利铂和/或伊立替康联合化疗（CT）治疗的转移性结直肠癌（CRC）患者中严重毒性的临床预测指标尚未发表。

著录项

来源
《Medical Oncology》 |2006年第3期|347-357|共11页
作者
Roberto Díaz; Jorge Aparicio; Jorge Molina; Laura Palomar; Alejandra Giménez; José Ponce; Ángel Segura; José Gómez-Codina;
展开▼
作者单位

Medical Oncology Unit University Hospital La Fe Avenida Campanar 19-21 46009 Valencia Spain;

Medical Oncology Unit University Hospital La Fe Avenida Campanar 19-21 46009 Valencia Spain;

Medical Oncology Unit University Hospital La Fe Avenida Campanar 19-21 46009 Valencia Spain;

Medical Oncology Unit University Hospital La Fe Avenida Campanar 19-21 46009 Valencia Spain;

Medical Oncology Unit University Hospital La Fe Avenida Campanar 19-21 46009 Valencia Spain;

Medical Oncology Unit University Hospital La Fe Avenida Campanar 19-21 46009 Valencia Spain;

Medical Oncology Unit University Hospital La Fe Avenida Campanar 19-21 46009 Valencia Spain;

Medical Oncology Unit University Hospital La Fe Avenida Campanar 19-21 46009 Valencia Spain;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Chemotherapy; toxicity; colorectal cancer; metastasis; irinotecan; oxaliplatin;

机译：化学疗法;毒性;大肠癌;转移;伊立替康;奥沙利铂;

相似文献

外文文献
中文文献
专利

1. 167 ORAL The XPD lys751gln polymorphism in colorectal cancer patients treated in first line chemotherapy with 5-FU-oxaliplatin or 5-FU-irinotecan combinations: a prognostic factor or a predictive marker of oxaliplatin efficiency? [J] . European Journal of Cancer Supplements . 2005,第2期

机译：167口服一线化疗联合5-FU-奥沙利铂或5-FU-伊立替康联合治疗的结直肠癌患者的XPD lys751gln多态性：奥沙利铂疗效的预后因素或预测指标？
2. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. [J] . Nobili S, Checcacci D, Filippelli F, Journal of chemotherapy . 2008,第5期

机译：对以伊立替康或奥沙利铂为基础的化疗预处理的转移性结直肠癌患者，每两月用奥沙利铂，伊立替康，输注5-氟尿嘧啶/亚叶酸进行化疗。
3. Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin. [J] . Han HS, Chang HJ, Hong YS, Diseases of the Colon and Rectum . 2009,第6期

机译：西妥昔单抗联合以伊立替康和奥沙利铂难治的基于伊立替康的化疗治疗转移性结直肠癌患者的表皮生长因子受体表达差异。
4. The Combination of Clinical, Dose-Related and Imaging Features Helps Predict Radiation-Induced Normal-Tissue Toxicity in Lung-cancer Patients -- An in-silico Trial Using Machine Learning Techniques [C] . Nalbantov G., Dekker A., De Ruysscher D., Machine Learning and Applications and Workshops (ICMLA), 2011 10th International Conference on . 2011

机译：临床，剂量相关和影像学特征的结合可帮助预测肺癌患者放射诱发的正常组织毒性-使用机器学习技术的计算机模拟试验
5. Use and outcomes of newer chemotherapeutic agents in colorectal cancer patients using Irinotecan as a case study. [D] . Obeidat, Nour A. 2008

机译：以伊立替康为例的结直肠癌患者中新型化疗药物的使用和结果。
6. Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1 irinotecan and bevacizumab as first-line therapy for metastatic colorectal cancer [O] . Yoshito Komatsu, Chikashi Ishioka, Ken Shimada, 2015

机译：TRICOLORE试验的研究方案：基于奥沙利铂的化疗与联合化疗联合S-1伊立替康和贝伐单抗作为转移性结直肠癌一线治疗的随机III期研究
7. Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy? [O] . Hiroki Osumi, Eiji Shinozaki, Mitsukuni Suenaga, 2015

机译：抗p53抗体的状态是否可预测以氟嘧啶，奥沙利铂和贝伐单抗作为一线化疗的转移性结直肠癌患者的临床结局？

Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer

摘要

著录项

相似文献

相关主题

期刊订阅